1. Lim KH, Counter CM. Leveling the playing field. Mol Cell. 2004 Aug27;15(4):491-2. PMID: 15327763
  2. Lim KH, Baines AT, Fiordalisi JJ, Shipitsin M, Feig LA, Cox AD, Der CJ, Counter CM. Activation of RalA is critical for Ras-induced tumorigenesis of human cells. Cancer Cell. 2005 Jun;7(6):533-45. PMID: 15950903
  3. Lim KH, Counter CM. Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. Cancer Cell. 2005 Nov;8(5):381-92. PMID: 16286246
  4. Baines AT, Lim KH, Shields JM, Lambert JM, Counter CM, Der CJ, Cox AD. Use of retrovirus expression of interfering RNA to determine the contribution of activated K-Ras and ras effector expression to human tumor cell growth. Methods Enzymol. 2006;407:556-74. PMID: 16757353
  5. Lim KH, O’Hayer K, Adam SJ, Kendall SD, Campbell PM, Der CJ, Counter CM. Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells. Curr Biol. 2006 Dec 19;16(24):2385-94. PMID: 17174914
  6. Ancrile B, Lim KH, Counter CM. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev. 2007 Jul 15;21(14):1714-9. PMID: 17639077, PMCID: PMC1920165
  7. Lim KH*, Ancrile BB*, Kashatus DF*, Counter CM. Tumour maintenance is mediated by eNOS. Nature. 2008 Apr 3;452(7187):646-9. doi: 10.1038/nature06778. Epub 2008 Mar. PMID: 18344980, PMCID: PMC2688829. (*co-first authors)
  8. Lee YS, Lim KH, Guo X, Kawaguchi Y, Gao Y, Barrientos T, Ordentlich P, Wang XF, Counter CM, Yao TP. The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer Res. 2008 Sep 15;68(18):7561-9. doi:10.1158/0008-5472.CAN-08-0188. PMID: 18794144, PMCID:PMC2978070
  9. Lim KH, Brady DC, Kashatus DF, Ancrile BB, Der CJ, Cox AD, Counter CM. Aurora-A phosphorylates, activates, and relocalizes the small GTPase RalA. Mol Cell Biol. 2010 Jan;30(2):508-23. doi: 10.1128/MCB.00916-08. Epub 2009 Nov 9. PMID: 19901077, PMCID: PMC2798468
  10. Issaq SH, Lim KH, Counter CM. Sec5 and Exo84 foster oncogenic ras-mediated tumorigenesis. Mol Cancer Res. 2010 Feb;8(2):223-31. doi:10.1158/1541-7786.MCR-09-0189. Epub 2010 Feb 9. PMID: 20145037, PMCID: PMC2824780
  11. Ngo VN*, Young RM*, Schmitz R*, Jhavar S*, Xiao W*, Lim KH*, Kohlhammer H, Xu W, Yang Y, Zhao H, Shaffer AL, Romesser P, Wright G, Powell J, Rosenwald A, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011 Feb 3;470(7332):115-9. doi: 10.1038/nature09671. Epub 2010 Dec 22.PMID: 21179087, PMCID: PMC5024568 (*co-first authors)
  12. Kashatus DF, Lim KH, Brady DC, Pershing NL, Cox AD, Counter CM. RALA and RALBP1 regulate mitochondrial fission at mitosis. Nat Cell Biol. 2011 Aug 7;13(9):1108-15. doi: 10.1038/ncb2310. PMID: 21822277, PMCID: PMC3167028
  13. Lim KH, Chung E, Khan A, Cao D, Linehan D, Ben-Josef E, Wang-Gillam A. Neoadjuvant therapy of pancreatic cancer: the emerging paradigm? Oncologist. 2012;17(2):192-200. doi: 10.1634/theoncologist.2011-0268. Epub 2012 Jan 16. PMID: 22250057, PMCID: PMC3286168
  14. Lim KH, Yang Y, Staudt LM. Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies. Immunol Rev. 2012 Mar;246(1):359-78. doi: 10.1111/j.1600-065X.2012.01105.x. PMID: 22435566, PMCID: PMC4094296
  15. Lim KH, Staudt LM. Toll-like receptor signaling. Cold Spring Harb Perspect Biol. 2013 Jan 1;5(1):a011247. doi: 10.1101/cshperspect.a011247. PMID: 23284045, PMCID: PMC3579400
  16. Teague A, Lim KH, Wang-Gillam A. Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies. Ther Adv Med Oncol. 2015 Mar;7(2):68-84. doi: 10.1177/1758834014564775. PMID:25755680, PMCID: PMC4346211
  17. Ur Rehman SS, Lim K, Wang-Gillam A. Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer. Expert Rev Anticancer Ther. 2016 May;16(5):485-92. doi: 10.1080/14737140.2016.1174581. Epub 2016 Apr 22. PMID: 27043737
  18. Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ, Cusworth BM, Toriola AT, Nieman RK, Worley LA, Yano M, Fowler KJ, Lockhart AC, Suresh R, Tan BR, Lim KH, Fields RC, Strasberg SM, Hawkins WG, DeNardo DG, Goedegebuure SP, Linehan DC. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol. 2016 May;17(5):651-62. doi: 10.1016/S1470-2045(16)00078-4. Epub 2016 Apr 4. PMID: 27055731, PMCID: PMC5407285
  19. Zhang D, Li L, Jiang H, Knolhoff BL, Lockhart AC, Wang-Gillam A, DeNardo DG, Ruzinova MB, Lim KH. Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2017 Apr 1;23(7):1748-1759. doi: 10.1158/1078-0432.CCR-16-1121. Epub 2016 Oct 4. PMID: 27702822, PMCID: PMC5378683
  20. Brauer DG, Strand MS, Sanford DE, Kushnir VM, Lim KH, Mullady DK, Tan BR Jr, Wang-Gillam A, Morton AE, Ruzinova MB, Parikh PJ, Narra VR, Fowler KJ, Doyle MB, Chapman WC, Strasberg SS, Hawkins WG, Fields RC. Utility of a multidisciplinary tumor board in the management of pancreatic and upper gastrointestinal diseases: an observational study. HPB (Oxford). 2017 Feb;19(2):133-139. doi: 10.1016/j.hpb.2016.11.002. Epub 2016 Dec 1. PMID: 27916436, PMCID: PMC5477647
  21. Wang-Gillam A, Lockhart AC, Tan BR, Suresh R, Singh PP, Lim KH, Pedersen K, Amin MA, Hawkins WG, DeNardo DG. Phase I study of defactinib combined with pembrolizumab and gemcitabine in advanced cancer.https://doi.org/10.1200/JCO.2018.36.4_suppl.380
  22. Brauer DG, Lim KH, Doyle MM, Hawkins WG, Chapman WC, Fields RC. Analysis of the effect of adjuvant therapy on overall survival for resected gallbladder adenocarcinoma using the National Cancer Database.https://doi.org/10.1200/JCO.2017.35.4_suppl.360
  23. Wang-Gillam A, Du L, Teague AS, Suresh R, Lim KH, Amin MA, Pedersen K, Tan BR, Huffman J, Lockhart AC. A phase I/II study combining tosedostat with capecitabine in patients with metastatic pancreatic ductal adenocarcinoma (PDAC). https://doi.org/10.1200/JCO.2017.35.4_suppl.410
  24. Zhang D, Li L, Jiang H, Knolhoff BL, Lockhart AC, Wang-Gillam A, DeNardo DG, Ruzinova MB, Lim KH. Constitutive IRAK4 activation underlies poor prognosis and chemoresistance in pancreatic ductal adenocarcinoma. Clinical cancer research. 2017 Apr 1;23(7):1748-59. https://doi.org/10.1158/1078-0432.CCR-16-1121
  25. Lim KH, Langley E, Gao F, Luo J, Li L, Meyer G, Kim P, Singh S, Kushnir VM, Early DS, Mullady DK, Edmundowicz SA, Wani S, Murad FM, Cao D, Azar RR, Wang-Gillam A. A clinically feasible multiplex proteomic immunoassay as a novel functional diagnostic for pancreatic ductal adenocarcinoma. Oncotarget. 2017 Apr 11;8(15):24250-24261. doi: 10.18632/oncotarget.15653. PMID: 28445954, PMCID: PMC5421844
  26. Lim KH, Lockhart AC, Waqar SN, Govindan R, Morgensztern D, Picus J, Tan BR, Baggstrom MQ, Ratchford E, Marquez S, Wang-Gillam A. Phase I study combining MLN8237 with nab-paclitaxel in patients with advanced solid malignancies. https://doi.org/10.1200/JCO.2017.35.15_suppl.2553
  27. Grierson P, Lim KH, Amin M. Immunotherapy in gastrointestinal cancers. J Gastrointest Oncol. 2017 Jun;8(3):474-484. doi: 10.21037/jgo.2017.05.01. PMID: 28736635, PMCID: PMC5506270
  28. Wang-Gillam A, Lim KH. Entering the molecular era of gastrointestinal oncology: current updates and challenges. J Gastrointest Oncol. 2017 Jun;8(3):377-378. PMID: 28736625, PMCID: PMC5506275
  29. Zhao DY, Lim KH. Current biologics for treatment of biliary tract cancers. J Gastrointest Oncol. 2017 Jun;8(3):430-440. doi: 10.21037/jgo.2017.05.04. PMID: 28736630, PMCID: PMC5506280
  30. Fakhri B, Lim KH. Molecular landscape and sub-classification of gastrointestinal cancers: a review of literature. J Gastrointest Oncol. 2017 Jun;8(3):379-386. doi: 10.21037/jgo.2016.11.01. PMID: 28736626, PMCID: PMC5506283
  31. Lee YS, Liu J, Fricano KA, Webb EM, Toolsie DR, Jones S, Rhoads JA, Vij R, Cashen AF, Abboud CN, Westervelt P, Bartlett NL, Dipersio JF, Kreisel FH, Lim KH. Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. Biol Blood Marrow Transplant. 2017 Dec;23(12):2199-2204. doi: 10.1016/j.bbmt.2017.08.022. Epub 2017 Aug 26. PMID: 28847710
  32. Regenbogen T, Chen L, Trinkaus K, Wang-Gillam A, Tan BR, Amin M, Pedersen KS, Park H, Suresh R, Lim KH, Ratchford E, Brown A, Lockhart AC. Pacritinib to inhibit JAK/STAT signaling in refractory metastatic colon and rectal cancer. J Gastrointest Oncol. 2017 Dec;8(6):985-989. doi: 10.21037/jgo.2017.08.16. PMID: 29299358, PMCID: PMC5750170
  33. Grierson P, Crites D, Ruzinova MB, Yano M, and Lim KH. Distinct clinical and magnetic resonance features of metastatic hepatocellular carcinoma treated with pembrolizumab: A case report of late response after pseudoprogression. Hepatology Communications 2018, 2: 148–151. doi:10.1002/hep4.1132
  34. Grierson P, Oza A, Doyle MM, Fowler K, Fields R, Hawkins WG, Hammill C, Wang-Gillam A, Amin MA, Pedersen K, Lim KH. Phase I study of hepatic arterial infusion (HAI) therapy with floxuridine (FUDR) combined with systemic gemcitabine and oxaliplatin in patients with locally advanced intrahepatic cholangiocarcinoma (ICC).https://doi.org/10.1200/JCO.2018.36.4_suppl.417
  35. Park H, Wang-Gillam A, Suresh R, Rigden CE, Amin MA, Tan BR, Pedersen K, Lim KH, Trikalinos N, Navo K, Morton A. A phase II trial of first-line FOLFIRINOX for patients with advanced gastroesophageal adenocarcinoma. https://doi.org/10.1200/JCO.2018.36.4_suppl.89
  36. Zhang D, Li L, Jiang H, Li Q, Wang-Gillam A, Yu J, Head R, Liu J, Ruzinova MB, Lim KH. Tumor-stroma IL-1β-IRAK4 feedforward circuitry drives tumor fibrosis, chemoresistance, and poor prognosis in pancreatic cancer. Cancer Res. 2018 Jan 23. pii: canres.1366.2017. doi: 10.1158/0008-5472.CAN-17-1366. PMID: 29363544
  37. Wang-Gillam A, Lockhart AC, Tan BR, Suresh R, Lim KH, Ratner L, DeNardo DG. Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer. https://doi.org/10.1200/JCO.2018.36.15_suppl.2561
  38. Jiang H, Xu M, Li L, Grierson P, Dodhiawala P, Highkin M, Zhang D, Li Q, Wang-Gillam A, Lim KH. Concurrent HER or PI3K Inhibition Potentiates the Antitumor Effect of the ERK Inhibitor Ulixertinib in Preclinical Pancreatic Cancer Models. Molecular cancer therapeutics. 2018;17(10):2144-55. doi:10.1136/gutjnl-2018-317424
  39. Li Q, Li L, Zhang D, Jiang H, Wang-Gillam A, Ruzinova MB, Lim KH. Constitutive IRAK4 activation contributes to NF-κB activity and chemoresistance in colorectal cancer. Cancer Research. 2018 Jul 1;78(13_Supplement):1941-.https://doi.org/10.1158/1538-7445.AM2018-1941
  40. Zhang D, Li L, Jiang H, Wang-Gillam A, Yu J, Head R, Liu J, Ruzinova MB, Lim KH. Tumor-stroma IL-1β-IRAK4 feedforward circuitry drives tumor fibrosis, chemo-resistance and is associated with poor prognosis in pancreatic cancer. Cancer Research. 2018 Jul 1;78(13_Supplement):995-. https://doi.org/10.1158/1538-7445.AM2018-995
  41. Kaseb AO, Sánchez NS, Sen S, Kelley RK, Tan BR, Bocobo AG, Lim KH, Abdel-Wahab R, Uemura MI, Carmagnani Pestana R, Qiao W, Xiao L, Morris J, Amin HM, Hassam MM, Rashid A, Banks KC, Lanman RB, Talasaz A, Mills Shaw KR, George B, Haque A, Raghav K, Wolf RA, Yao JC, Meric-Bernstam F, Ikeda S, Kurzrock R. Molecular profiling of hepatocellular carcinoma using circulating cell-free DNA. Clin Cancer Res. 2019 Jul 30;. doi: 10.1158/1078-0432.CCR-18-3341. [Epub ahead of print] PubMed PMID: 31363003.
  42. Heo GS, Detering L, Luehmann HP, Primeau T, Lee YS, Laforest R, Li S, Stec J, Lim KH, Lockhart AC, Liu Y. Folate Receptor alpha-Targeted (89)Zr-M9346A Immuno-PET for Image-Guided Intervention with Mirvetuximab Soravtansine in Triple-Negative Breast Cancer. Mol Pharm. 2019;16(9):3996-4006.
  43. Li Q, Chen Y, Zhang D, Grossman J, Li L, Khurana N, Jiang H, Grierson PM, Herndon J, DeNardo DG, Challen GA, Liu J, Ruzinova MB, Fields RC, Lim KH. IRAK4 mediates colitis-induced tumorigenesis and chemoresistance in colorectal cancer. JCI Insight. 2019 Oct 3;4(19). pii: 130867. doi: 10.1172/jci.insight.130867. PMID: 31527315
  44. Jiang H, Liu X, Knolhoff B, Hegde S, Lee K, Jiang H, Fields R, Pachter J, Lim KH, DeNardo D, 2020. Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion. Gut69(1), pp.122-132.
  45. Cercek A, Boerner T, Tan BR, Chou JF, Gonen M, Boucher TM, Hauser HF, Do RKG, Lowery MA, Harding JJ, Varghese AM, Reidy-Lagunes D, Saltz L, Schultz N, Kingham TP, D’Angelica MI, DeMatteo RP, Drebin JA, Allen PJ, Balachandran VP, Lim KH, Sanchez-Vega F, Vachharajani N, Majella Doyle MB, Fields RC, Hawkins WG, Strasberg SM, Chapman WC, Diaz LA, Jr., Kemeny NE, Jarnagin WR. Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2019.
  46. Grierson P, Teague A, Suresh R, Lim KH, Amin M, Pedersen K, Tan B, Huffman J, Boice N, Du L, Liu J, Lockhart AC, Wang-Gillam A. Phase Ib/II study combining tosedostat with capecitabine in patients with advanced pancreatic adenocarcinoma. J Gastrointest Oncol. 2020 Feb;11(1):61-67. doi: 10.21037/jgo.2019.11.06. PubMed PMID: 32175106; PubMed Central PMCID: PMC7052765.
  47. Rozenblatt-Rosen O, Regev A, Oberdoerffer P, Nawy T, Hupalowska A, Rood JE, Ashenberg O, Cerami E, Coffey RJ, Demir E, Ding L, Esplin ED, Ford JM, Goecks J, Ghosh S, Gray JW, Guinney J, Hanlon SE, Hughes SK, Hwang ES, Iacobuzio-Donahue CA, Jané-Valbuena J, Johnson BE, Lau KS, Lively T, Mazzilli SA, Pe’er D, Santagata S, Shalek AK, Schapiro D, Snyder MP, Sorger PK, Spira AE, Srivastava S, Tan K, West RB, Williams EH. The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. Cell. 2020 Apr 16;181(2):236-249. doi: 10.1016/j.cell.2020.03.053. Review. PubMed PMID: 32302568.
  48. Park H, Jin RU, Wang-Gillam A, Suresh R, Rigden C, Amin M, Tan BR, Pedersen KS, Lim KH, Trikalinos NA, Acharya A, Copsey ML, Navo KA, Morton AE, Gao F, Lockhart AC. FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial. JAMA Oncol2020 May 29;doi: 10.1001/jamaoncol.2020.2020. PubMed PMID: 32469386; PubMed Central PMCID: PMC7260693.
  49. Dang HX, Krasnick BA, White BS, Grossman JG, Strand MS, Zhang J, Cabanski CR, Miller CA, Fulton RS, Goedegebuure SP, Fronick CC, Griffith M, Larson DE, Goetz BD, Walker JR, Hawkins WG, Strasberg SM, Linehan DC, Lim KH, Lockhart AC, Mardis ER, Wilson RK, Ley TJ, Maher CA, Fields RC. The clonal evolution of metastatic colorectal cancer. Sci Adv. 2020;6(24):eaay9691.
  50. Dodhiawala PB, Khurana N, Zhang D, Cheng Y, Li L, Seehra K, Jiang H, Grierson PM, Wang-Gillam A, Ruzinova MB, Lim KH. Essential role of IRAK4/TPL2 signaling axis in MAPK activation by oncogenic RAS and genotoxic stress. Cancer Research. 2020 Aug 15;80(16_Supplement):3039-.
  1. Dodhiawala PB, Khurana N, Zhang D, Cheng Y, Li L, Wei Q, Seehra K, Jiang H, Grierson PM, Wang-Gillam A, Lim KH. TPL2 enforces RAS-induced inflammatory signaling and is activated by point mutations. J Clin Invest. 2020 Jun 23:137660. doi: 10.1172/JCI137660.
  1. Khurana N, Dodhiawala PB, Bulle A, Lim KH. Deciphering the Role of Innate Immune NF-kB Pathway in Pancreatic Cancer. Cancers (Basel). 2020;12(9).(1)https://doi.org/10.3390/cancers12092675
  2. Bulle A, Lim KH. Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer. Signal Transduct Target Ther. 2020;5(1):249.https://doi.org/10.1038/s41392-020-00341-1
  3. Chin RI, Roy A, Pedersen K, Hunt S, Mutch M, Glasgow S, Silviera M, Wise P, Smith R, Wang-Gillam A, Tan B, Lim KH, Suresh R, Amin M, Roach M, Badiyan S, Henke L, Kim H. Complete clinical response after short-course radiation and sequential multi-agent chemotherapy for non-operative treatment of rectal adenocarcinoma. International Journal of Radiation Oncology, Biology, Physics. 2020 Nov 1;108(3):S47-8.https://doi.org/10.1016/j.ijrobp.2020.07.2163
  4. Panni UY, Chen MY, Zhang F, Cullinan DR, Li L, James CA, Zhang X, Rogers S, Alarcon A, Baer JM, Zhang D, Gao F, Miller C, Gong Q, Lim KH, DeNardo D, Goedegebuure S, Gillanders W, Hawkins W. Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cancer immunobiology. Cancer Immunology, Immunotherapy. 2023 Aug;72(8):2813-27. https://doi.org/10.1007/s00262-023-03463-x
  5. Storrs EP, Chati P, Usmani A, Sloan I, Krasnick BA, Babbra R, Harris PK, Sachs CM, Qaium F, Chatterjee D, Wetzel C, Goedegebuure S, Hollander T, Anthony H, Ponce J, Khaliq A, Badiyan S, Kim H, Denardo D, Lang G, Cosgrove N, Kushnir v, Early D, Masood A, Lim KH, Hawkins W, Ding L, Fields R, Das K, Chaudhuri A. High-dimensional deconstruction of pancreatic cancer identifies tumor microenvironmental and developmental stemness features that predict survival. npj Precision Oncology. 2023 Oct 19;7(1):105. https://doi.org/10.1038/s41698-023-00455-z
  6. Grierson PM, Suresh R, Tan B, Pedersen KS, Amin M, Park H, Trikalinos NA, Liu J, Boice N, Brown A, Bansod S, Wang-Gillam A, Lim KH. A pilot study of paricalcitol plus nanoliposomal irinotecan and 5-FU/LV in advanced pancreatic cancer patients after progression on gemcitabine-based therapy. Clinical Cancer Research. 2023 Dec 1;29(23):4733-9. https://doi.org/10.1158/1078-0432.CCR-23-1405
  7. Zhang X, Detering L, Sultan D, Luehmann H, Li L, Heo GS, Zhang X, Lou L, Grierson PM, Greco S, Ruzinova M, Laforest R, Dehdashti F, Lim KH, Liu Y. CC chemokine receptor 2-targeting copper nanoparticles for positron emission tomography-guided delivery of gemcitabine for pancreatic ductal adenocarcinoma. ACS nano. 2021 Jan 6;15(1):1186-98.https://doi.org/10.1021/acsnano.0c08185
  8. Wu Y, Chen S, Yang X, Sato K, Lal P, Wang Y, Shinkle AT, Wendl MC, Primeau TM, Zhao Y, Gould A, Sun H, Mudd J, Hoog J, Mashl R, Wyczalkowski M, Chia-Kuei M, Liu R, Herndon J, Davies S, Liu D, Ding X, Evrard Y, Welm B, Lum D, Koh M, Welm A, Chuang J, Moscow J, Meric-Bernstam F, Govindan R, Li S, Hsieh J, Fields R, Lim KH, Ma C, Zhang H, Ding L, Chen F. Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma. Cancer research. 2023 Dec 15;83(24):4161-78.
  9. Garcia-Manero G, Platzbecker U, Lim KH, Nowakowski G, Abdel-Wahab O, Kantarjian H, Verma A, Starczynowski DT. Research and clinical updates on IRAK4 and its roles in inflammation and malignancy: themes and highlights from the 1st symposium on IRAK4 in cancer. Frontiers in Hematology. 2024 Feb 15;3:1339870.https://doi.org/10.3389/frhem.2024.1339870
  10. Bulle A, Liu P, Seehra K, Bansod S, Chen Y, Zahra K, Somani V, Khawar IA, Chen HP, Dodhiawala PB, Li L, Geng Y, Chia-Kuei M, Mahsl J, Ding L, Ramaswamy G, Davies S, Mudd J, Hawkins W, Fields R, DeNardo D, Knoerzer D, Held J, Grierson P, Wang-Gillam A, Ruzinova M, Lim KH. Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer. Nature Communications. 2024 Mar 20;15(1):2503.https://doi.org/10.1038/s41467-024-46811-w

Print Friendly, PDF & Email